GALVUMET 50/500 vildagliptin 50 mg/metformin hydrochloride 500 mg film coated tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

galvumet 50/500 vildagliptin 50 mg/metformin hydrochloride 500 mg film coated tablet blister pack

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; titanium dioxide; magnesium stearate; purified talc; iron oxide yellow; iron oxide red; hyprolose - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Clavudale 200 mg/50 mg tablets for dogs Irland - engelsk - HPRA (Health Products Regulatory Authority)

clavudale 200 mg/50 mg tablets for dogs

dechra regulatory b.v. - amoxicillin trihydrate; potassium clavulanate - tablet - 200, 50 mg/tablet - amoxicillin and enzyme inhibitor

Clavudale 400 mg/100 mg tablets for dogs Irland - engelsk - HPRA (Health Products Regulatory Authority)

clavudale 400 mg/100 mg tablets for dogs

dechra regulatory b.v. - amoxicillin trihydrate; potassium clavulanate - tablet - 400, 100 mg/tablet - amoxicillin and enzyme inhibitor

Carprieve 20 mg Tablets for Dogs Irland - engelsk - HPRA (Health Products Regulatory Authority)

carprieve 20 mg tablets for dogs

norbrook laboratories (ireland) limited - carprofen - tablet - 20 mg/tablet - carprofen

Carprieve 50 mg Tablets for Dogs Irland - engelsk - HPRA (Health Products Regulatory Authority)

carprieve 50 mg tablets for dogs

norbrook laboratories (ireland) limited - carprofen - tablet - 50 mg/tablet - carprofen

Carprogesic 20 mg Tablets for dogs Irland - engelsk - HPRA (Health Products Regulatory Authority)

carprogesic 20 mg tablets for dogs

norbrook laboratories (ireland) limited - carprofen - tablet - 20 mg/tablet - carprofen

Carprogesic 50 mg Tablets for dogs Irland - engelsk - HPRA (Health Products Regulatory Authority)

carprogesic 50 mg tablets for dogs

norbrook laboratories (ireland) limited - carprofen - tablet - 50 mg/tablet - carprofen

ALPHAPRESS 50 hydralazine hydrochloride 50 mg tablet bottle Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapress 50 hydralazine hydrochloride 50 mg tablet bottle

alphapharm pty ltd - hydralazine hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; purified talc; disodium edetate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; iron oxide yellow; macrogol 4000; erythrosine - this product accepted for registration as 'currently supplied' at the time of commencement of the act. amended product information (variation to pregnancy statement) was approved as specified in the letter of 13 august 92 from dr bijoy varma. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

CLOPIXOL zuclopenthixol 10 mg (as zuclopenthixol hydrochloride) tablet bottle Australia - engelsk - Department of Health (Therapeutic Goods Administration)

clopixol zuclopenthixol 10 mg (as zuclopenthixol hydrochloride) tablet bottle

lundbeck australia pty ltd - zuclopenthixol hydrochloride, quantity: 11.8 mg (equivalent: zuclopenthixol, qty 10 mg) - tablet, film coated - excipient ingredients: copovidone; purified talc; microcrystalline cellulose; lactose monohydrate; glycerol; potato starch; magnesium stearate; hydrogenated castor oil; titanium dioxide; hypromellose; macrogol 6000; iron oxide red - safety related notification and ammended text of the product information approved as described in the letter dated 28 may 2008 from ceu1. (sub#2008-1319-1) clopixol tablets: acute and chronic schizophrenia and other psychoses, especially those with symptoms such as hallucinations, delusions, thought disturbances, agitation, restlessness, hostility or aggressiveness. manic phase of manic depressive illness.

APO-MEBEVERINE mebeverine hydrochloride 135 mg tablet blister pack Australia - engelsk - Department of Health (Therapeutic Goods Administration)

apo-mebeverine mebeverine hydrochloride 135 mg tablet blister pack

arrotex pharmaceuticals pty ltd - mebeverine hydrochloride, quantity: 135 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; microcrystalline cellulose; povidone; sodium starch glycollate type a; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose - apo-mebeverine tablets are indicated in the management of the irritable bowel syndrome ('irritable colon', 'spastic colon', 'functional bowel disorders', 'spastic constipation', 'nervous diarrhoea'). apo-mebeverine is used to treat the symptoms of this condition - i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.